The stock of Thermo Fisher Scientific Inc (TMO) has gone down by -1.31% for the week, with a 3.07% rise in the past month and a -13.32% drop in the past quarter. The volatility ratio for the week is 1.64%, and the volatility levels for the past 30 days are 1.93% for TMO. The simple moving average for the past 20 days is 0.81% for TMO’s stock, with a -8.03% simple moving average for the past 200 days.
Is It Worth Investing in Thermo Fisher Scientific Inc (NYSE: TMO) Right Now?
Thermo Fisher Scientific Inc (NYSE: TMO) has a price-to-earnings ratio that is above its average at 33.16x. The stock has a 36-month beta value of 0.77. Opinions on the stock are mixed, with 17 analysts rating it as a “buy,” 8 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TMO is 381.98M, and at present, short sellers hold a 0.93% of that float. On December 18, 2024, the average trading volume of TMO was 1.67M shares.
TMO) stock’s latest price update
Thermo Fisher Scientific Inc (NYSE: TMO) has experienced a decline in its stock price by -0.27 compared to its previous closing price of 530.26. However, the company has seen a fall of -1.31% in its stock price over the last five trading days. zacks.com reported 2024-12-17 that TMO’s recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
Analysts’ Opinion of TMO
Stephens, on the other hand, stated in their research note that they expect to see TMO reach a price target of $680. The rating they have provided for TMO stocks is “Overweight” according to the report published on October 01st, 2024.
Wells Fargo gave a rating of “Overweight” to TMO, setting the target price at $670 in the report published on August 28th of the current year.
TMO Trading at -3.71% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.77% of loss for the given period.
Volatility was left at 1.93%, however, over the last 30 days, the volatility rate increased by 1.64%, as shares surge +5.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.69% lower at present.
During the last 5 trading sessions, TMO fell by -1.31%, which changed the moving average for the period of 200-days by -9.08% in comparison to the 20-day moving average, which settled at $524.58. In addition, Thermo Fisher Scientific Inc saw -0.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from CASPER MARC N, who sale 10,000 shares at the price of $532.20 back on Dec 03 ’24. After this action, CASPER MARC N now owns 101,192 shares of Thermo Fisher Scientific Inc, valued at $5,321,955 using the latest closing price.
CASPER MARC N, the Chairman & CEO of Thermo Fisher Scientific Inc, sale 10,000 shares at $530.26 during a trade that took place back on Dec 02 ’24, which means that CASPER MARC N is holding 111,192 shares at $5,302,604 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.14. The total capital return value is set at 0.08. Equity return is now at value 13.01, with 6.22 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.72. The interest coverage ratio of the stock is 4.9.
Currently, EBITDA for the company is 11.2 billion with net debt to EBITDA at 2.71. When we switch over and look at the enterprise to sales, we see a ratio of 5.5. The receivables turnover for the company is 4.33for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To sum up, Thermo Fisher Scientific Inc (TMO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
